AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
The UK government has one eye on the short-term, securing a supply of COVID-19 vaccines, but also towards future potential vaccines against the flu or other infectious diseases. During the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback